On Aug. 18, the U.S. Food and Drug Administration (FDA) approved Addyi (flibanserin) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. Read more.
FDA approves drug for sexual desires disorders in women
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.
